Skip to main content

Table 2 Characteristics of cannabinoid-based medicines

From: Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study

Survey item subject (number of responses to item) Multiple choice options for survey responses All respondents (%) Respondents < 13 years (%)
CBM type*
 N all respondents = 60
 N < 13y = 19
Oil/paste 46 (76.7) 11 (57.9)
Dried flower/Flos 33 (55.0) 2 (10.5)
Edible 29 (48.3) 2 (10.5)
Tincture 17 (28.3) 3 (15.8)
Other liquid form 11 (18.3) 1 (5.3)
Pill 5 (8.3)
Total CBM types used 141 19
Mean per participant 2.4 (± 1.5) 1.0 (± 0.7)
CBM route of administration*
 N all respondents = 60
 N < 13y = 19
Topical 36 (60.0) 12 (63.2)
Ingested 36 (60.0) 4 (21.1)
Inhaled 33 (55.0)
Sublingual 23 (38.3) 4 (21.1)
Total routes reported 128 20
Mean per participant 2.1 (± 1.1) 1.1 (± 0.8)
Topical CBM type*
 N all respondents = 36
 N < 13y = 19
Cream 24 (66.7) 8 (42.1)
Oil 23 (63.9) 6 (31.6)
Lotion 12 (33.3) 4 (21.1)
Spray 3 (8.3) 1 (5.3)
Foam
Total types of topicals 62 19
Mean per participant 1.7 (± 1.1) 1.1 (± 1.2)
Composition of CBM (THC vs. CBD)*
 N All Respondents = 58
 N < 13y = 19
THC only 18 (15.3)
THC/CBD combination 41 (34.7) 6 (31.6)
CBD only 24 (20.3) 9 (47.4)
Unknown 35 (29.7) 4 (21.1)
Total compositions reported 118 19
Current frequency of CBM administration
 N all respondents = 51
 N < 13y = 10
Less than once per week 5 (9.8) 2 (20.0)
Once per week 2 (3.9)
Several times per week 8 (15.7) 1 (10.0)
Once per day 15 (29.4) 4 (40.0)
Several times per day 19 (37.3) 2 (20.0)
Unsure 2 (3.9) 1 (10.0)
Change over time: dose of CBM
 N all respondents = 52
 N < 13y = 11
Dose decreased 6 (11.5) 1 (9.1)
Dose remained stable 13 (25.0) 2 (18.2)
Dose increased 13 (25.0) 4 (36.4)
Dose fluctuated 17 (32.7) 2 (18.2)
Unsure 3 (5.8) 2 (18.2)
Change over time: frequency of CBM administration
 N all respondents = 52
 N < 13y = 11
Administered less frequently 7 (13.5) 1 (9.1)
Frequency remained stable 17 (32.7) 3 (27.3)
Administered more frequently 9 (17.3) 2 (18.2)
Administration frequency fluctuated 17 (32.7) 4 (36.4)
Unsure 2 (3.8) 1
CBM source of acquisition*
 N All Respondents = 50
 N < 13y = 10
Cannabis dispensary 31 (62.0) 6 (60.0)
Social connection 19 (38.0) 2 (20.0)
Internet web-shops 6 (12.0) 4 (40.0)
Medical pharmacy 5 (10.0) 1 (10.0)
Cultivated at home 4 (8.0)
Prefer not to answer 1 (2.0)
Total number of sources 66 (100) 13 (100)
Preferred route of administration
 N all respondents = 44
 N < 13y = 9
Topical 11 (25.0) 4 (44.4)
Inhaled 18 (40.9)  
Ingested 10 (22.7) 2 (22.2)
Sublingual 5 (11.4) 3 (33.3)
Duration of use
 N all respondents = 52
 N < 13y = 11
 < 6 months
6 months–1 year
1–5 years
 > 5 years
13 (25.0)
7 (13.5)
18 (34.6)
14 (26.9)
5 (45.5)
4 (36.4)
2 (18.2)
Reported side effects*
 N all respondents = 45
 N < 13y = 9
Dry mouth 20 (44.4)
Cough/wheezing 13 (28.8)
Dry/red eyes 12 (26.7) 1 (11.1)
Fatigue 10 (22.2)
Dizziness 7 (15.6)
Paranoia 3 (6.7)
Problems with memory/attention 3 (6.7)
Problems with coordination 3 (6.7)
CBM prescribed by physician
 N all respondents = 50
 N < 13y = 10
Yes 12 (24.0) 1 (10.0)
No 38 (76.0) 9 (90.0)
Physician aware of CBM use
 N all respondents = 50
 N < 13y = 9
Yes 28 (73.7) 7 (77.8)
No 10 (26.3) 2 (22.2)
  1. Reported cannabinoid-based medicines (CBMs) and characteristics of administration in the total cohort. * Indicates that participants were able to select more than one response. Participants were not required to respond to each item. Administration by way of suppositories were not reported by any participant
  2. THC: delta-9-tetrahydrocannabinol, CBD: cannabidiol